E-viri
Recenzirano
Odprti dostop
-
Rimini, Margherita; Fornaro, Lorenzo; Lonardi, Sara; Niger, Monica; Lavacchi, Daniele; Pressiani, Tiziana; Lucchetti, Jessica; Giordano, Guido; Pretta, Andrea; Tamburini, Emiliano; Pirrone, Chiara; Rapposelli, Ilario Giovanni; Diana, Anna; Martinelli, Erika; Garajová, Ingrid; Simionato, Francesca; Schirripa, Marta; Formica, Vincenzo; Vivaldi, Caterina; Caliman, Enrico; Rizzato, Mario Domenico; Zanuso, Valentina; Nichetti, Federico; Angotti, Lorenzo; Landriscina, Matteo; Scartozzi, Mario; Ramundo, Matteo; Pastorino, Alessandro; Daniele, Bruno; Cornara, Noemi; Persano, Mara; Gusmaroli, Eleonora; Cerantola, Riccardo; Salani, Francesca; Ratti, Francesca; Aldrighetti, Luca; Cascinu, Stefano; Rimassa, Lorenza; Antonuzzo, Lorenzo; Casadei‐Gardini, Andrea
Liver international, August 2023, 2023-08-00, 20230801, Letnik: 43, Številka: 8Journal Article
Background The TOPAZ‐1 phase III trial reported a survival benefit with the anti‐programmed death cell ligand 1 (anti‐PD‐L1) durvalumab in combination with gemcitabine and cisplatin in patients with advanced biliary tract cancer. The present study investigated the efficacy and safety of this new standard treatment in a real‐world setting. Methods The analysed population included patients with unresectable, locally advanced or metastatic adenocarcinoma of the biliary tract treated with durvalumab in combination with gemcitabine and cisplatin at 17 Italian centres. The primary endpoint of the study was progression‐free survival (PFS), whereas secondary endpoints included overall survival (OS), overall response rate (ORR) and safety. Unadjusted and adjusted hazard ratios (HRs) by baseline characteristics were calculated using the Cox proportional hazards model. Results From February 2022 to November 2022, 145 patients were enrolled. After a median follow‐up of 8.5 months (95% CI: 7.9–13.6), the median PFS was 8.9 months (95% CI: 7.4–11.7). Median OS was 12.9 months (95% CI: 10.9–12.9). The investigator‐assessed confirmed ORR was 34.5%, and the disease control rate was 87.6%. Any grade adverse events (AEs) occurred in 137 patients (94.5%). Grades 3–4 AEs occurred in 51 patients (35.2%). The rate of immune‐mediated AEs (imAEs) was 22.7%. Grades 3–4 imAEs occurred in 2.1% of the patients. In univariate analysis, non‐viral aetiology, ECOG PS >0 and NLR ≥3 correlated with shorter PFS. Conclusion The results reported in this first real‐world analysis mostly confirmed the results achieved in the TOPAZ‐1 trial in terms of PFS, ORR and safety.
Avtor
Vnos na polico
Trajna povezava
- URL:
Faktor vpliva
Dostop do baze podatkov JCR je dovoljen samo uporabnikom iz Slovenije. Vaš trenutni IP-naslov ni na seznamu dovoljenih za dostop, zato je potrebna avtentikacija z ustreznim računom AAI.
Leto | Faktor vpliva | Izdaja | Kategorija | Razvrstitev | ||||
---|---|---|---|---|---|---|---|---|
JCR | SNIP | JCR | SNIP | JCR | SNIP | JCR | SNIP |
Baze podatkov, v katerih je revija indeksirana
Ime baze podatkov | Področje | Leto |
---|
Povezave do osebnih bibliografij avtorjev | Povezave do podatkov o raziskovalcih v sistemu SICRIS |
---|
Vir: Osebne bibliografije
in: SICRIS
To gradivo vam je dostopno v celotnem besedilu. Če kljub temu želite naročiti gradivo, kliknite gumb Nadaljuj.